Clinical Pharmacist Intervention to Reduce Drug-related Readmissions Among Older People
ConditionDrug Use
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age75+
SponsorUmeå University
About this trial
This randomized controlled trial primarily investigates if a clinical pharmacist intervention can reduce drug-related readmissions among patients \>75 years. The intervention targets the transfer between hospital and primary care. In brief, the intervention includes medical chart reviews and patient interviews during a period of 180 days.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Living at home
Acutely admitted
Registered at one of ten pre-specified primary care health centers
Disqualifiers
Patients unable to communicate or who do not speak Swedish
Patients scheduled for palliative care
Patients admitted due to intoxication by alcohol or drug (non prescription)
Trial design
Design model
Parallel
Treatments tested in this trial
Enhanced clinical pharmacist service
Other interventionThe intervention includes regular medical chart reviews, multiple patient interviews and, if needed, collaboration with the primary care physician.
Treatment groups
700 Participants
are divided into 2 treatment groupsGroup A: Intervention groupExperimental treatment 1 intervention
Group B: Control groupNo intervention 0 interventions
Trial outcomes
Primary outcomes
1
Time from discharge to first drug-related readmission
Survival analysis with drug-related readmission as endpoint
Time frame
180 daysSecondary outcomes
1
Time from discharge to first drug-related readmission
Survival analysis with drug-related readmission as endpoint
Time frame
30 days2
Frequency of drug-related readmissions
Difference in total number of drug-related readmissions
Time frame
30 and 180 days3
Time from discharge to first drug-related readmission - subgroups with/without heart failure
Survival analysis among patients with/without heart failure
Time frame
30 and 180 days4
Time from discharge to first drug-related readmission - subgroups with/without cognitive impairment
Survival analysis among patients with/without cognitive impairment
Time frame
30 and 180 daysSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov